These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1410 related articles for article (PubMed ID: 32028981)

  • 1. BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition.
    Niu W; Luo Y; Zhou Y; Li M; Wu C; Duan Y; Wang H; Fan S; Li Z; Xiong W; Li X; Li G; Ren C; Li H; Zhou M
    J Exp Clin Cancer Res; 2020 Feb; 39(1):30. PubMed ID: 32028981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Non-Coding RNA (LncRNA) HOXA11-AS Promotes Breast Cancer Invasion and Metastasis by Regulating Epithelial-Mesenchymal Transition.
    Li W; Jia G; Qu Y; Du Q; Liu B; Liu B
    Med Sci Monit; 2017 Jul; 23():3393-3403. PubMed ID: 28701685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 4. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo.
    Yang W; Shan Z; Zhou X; Peng L; Zhi C; Chai J; Liu H; Yang J; Zhang Z
    Cancer Biomark; 2018; 23(4):589-601. PubMed ID: 30475755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition.
    Song R; Zhang J; Huang J; Hai T
    Cancer Biomark; 2018; 22(3):565-573. PubMed ID: 29843220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of lncRNA ZEB2NAT suppresses epithelial mesenchymal transition, metastasis and proliferation in breast cancer cells.
    Eroğlu Güneş C; Güçlü E; Vural H; Kurar E
    Gene; 2021 Dec; 805():145904. PubMed ID: 34418470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol Inhibits the Migration and Metastasis of MDA-MB-231 Human Breast Cancer by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition.
    Sun Y; Zhou QM; Lu YY; Zhang H; Chen QL; Zhao M; Su SB
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30901941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YB1 regulates miR-205/200b-ZEB1 axis by inhibiting microRNA maturation in hepatocellular carcinoma.
    Liu X; Chen D; Chen H; Wang W; Liu Y; Wang Y; Duan C; Ning Z; Guo X; Otkur W; Liu J; Qi H; Liu X; Lin A; Xia T; Liu HX; Piao HL
    Cancer Commun (Lond); 2021 Jul; 41(7):576-595. PubMed ID: 34110104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of Y‑box‑binding protein‑1 inhibits the malignant progression of HT‑29 colorectal adenocarcinoma cells by reversing epithelial‑mesenchymal transition.
    Yan XB; Zhu QC; Chen HQ; Peng JY; Chao HL; Du HX; Wang ZG; Jin ZM
    Mol Med Rep; 2014 Nov; 10(5):2720-8. PubMed ID: 25201740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer.
    Li Y; Su X; Pan H
    Cancer Biomark; 2019; 25(2):185-192. PubMed ID: 31104011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1.
    Wang X; Zhou X; Zeng F; Wu X; Li H
    Breast Cancer; 2020 Jul; 27(4):765-775. PubMed ID: 32144736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop.
    Du X; Tu Y; Liu S; Zhao P; Bao Z; Li C; Li J; Pan M; Ji J
    J Cell Mol Med; 2020 Jan; 24(2):1474-1487. PubMed ID: 31856394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition.
    Gao Y; Ma H; Gao C; Lv Y; Chen X; Xu R; Sun M; Liu X; Lu X; Pei X; Li P
    J Transl Med; 2018 Feb; 16(1):38. PubMed ID: 29471858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LincK contributes to breast tumorigenesis by promoting proliferation and epithelial-to-mesenchymal transition.
    Li J; Hao Y; Mao W; Xue X; Xu P; Liu L; Yuan J; Zhang D; Li N; Chen H; Zhao L; Sun Z; Luo J; Chen R; Zhao RC
    J Hematol Oncol; 2019 Feb; 12(1):19. PubMed ID: 30795783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Liao YM; Wang YH; Hung JT; Lin YJ; Huang YL; Liao GS; Hsu YL; Wu JC; Yu AL
    Breast Cancer Res; 2021 Jan; 23(1):5. PubMed ID: 33413566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
    Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
    Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cullin3 promotes breast cancer cells metastasis and epithelial-mesenchymal transition by targeting BRMS1 for degradation.
    Huo X; Li S; Shi T; Suo A; Ruan Z; Guo H; Yao Y
    Oncotarget; 2015 Dec; 6(39):41959-75. PubMed ID: 26544623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF‑κB signaling pathway.
    Wang M; Wu Y; Li X; Dai M; Li S
    Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37539706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
    Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
    Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.